Table 2.
Differences in the characteristics of subjects with type 1 diabetes who progressed vs those who did not progress over 3 years
| Variable | Progressors = 24 | Non-progressors = 17 | P value |
|---|---|---|---|
| Age , years | 37 ±14 | 33±12 | 0.30 |
| Duration, years | 13±6 | 14±7 | 0.51 |
| BMI, kg/m2 | 25±5 | 28±4 | 0.03 |
| Systolic BP, mm Hg | 117±13 | 117±10 | 0.98 |
| Diastolic BP, mm Hg | 73±7 | 72±9 | 0.79 |
|
Mean Daytime Systolic BP, mm Hg |
125 ± 9 | 128± 10 | 0.71 |
|
Mean Daytime Diastolic BP, mm Hg |
75 ± 9 | 78 ± 6 | 0.21 |
|
Mean Nighttime Systolic BP, mm Hg |
123 ± 9 | 112 ± 10 | 0.25 |
|
Mean Nighttime Diastolic BP, mm Hg |
65± 11 | 71 ± 7 | 0.22 |
| HbA1c,% | 8±1.3 | 7.8±1.2 | 0.64 |
| HbA1c, mmol/mol | 64±22 | 58±21 | 0.64 |
| Cholesterol , mg/dl | 174±31 | 161±25 | 0.13 |
| LDL-c, mg/dl | 95±25 | 88±17 | 0.42 |
| HDL-c, mg/dl | 66±23 | 61±16 | 0.46 |
| Triglycerides, mg/dl | 73±28 | 60±20 | 0.13 |
| Serum Creatinine, mg/dl | 0.9±0.2 | 0.8±0.2 | 0.63 |
| AUC Hypo | 2907±3362 | 2420±2336 | 0.79 |
| AUC Hyper | 2874±4362 | 2790±4336 | 0.65 |
| HBGI | 9.3±6 | 10.8±8.3 | 0.77 |
| LBGI | 3±2.9 | 2.6±2.3 | 0.74 |
| MAGE | 125±35.1 | 139.6±33.6 | 0.67 |
| IFN-g,pg/mL | 12.6±26.6 | 7.5±8.3 | 0.84 |
| IL-10, pg/mL | 15.2±26.2 | 13.8±24.9 | 0.92 |
| IL-17A, pg/mL | 6.1±6.2 | 4.1±5.2 | 0.12 |
| MCP-1, pg/mL | 647±245 | 548±248 | 0.25 |
| TNF-a, pg/mL | 8.7±2.9 | 7±2.1 | 0.05 |
| CRP, ng/mL | 3±4.7 | 1.7±2.1 | 0.28 |
Data are presented as mean ± SD. BMI: body mass index, BP: blood pressure, LDL low density lipoprotein, HDL: high density lipoprotein, DySF: dynamic stress factor, HBGI: high blood glucose index, LBGI: low blood glucose index, MAGE: mean amplitude of glycemic index , AUC: area under the curve,IFN-g: interferon gamma, IL: interleukin, MCP: Monocyte chemoattractant protein-1, TNF-a: tumor necrosis factor alpha, R: receptor, CRP: c reactive protein